DK1003559T3 - Immobilisering af vitamin A-syre ved kationiske polyelektrolytter - Google Patents

Immobilisering af vitamin A-syre ved kationiske polyelektrolytter

Info

Publication number
DK1003559T3
DK1003559T3 DK98942616T DK98942616T DK1003559T3 DK 1003559 T3 DK1003559 T3 DK 1003559T3 DK 98942616 T DK98942616 T DK 98942616T DK 98942616 T DK98942616 T DK 98942616T DK 1003559 T3 DK1003559 T3 DK 1003559T3
Authority
DK
Denmark
Prior art keywords
vitamin
acid
immobilization
cationic polyelectrolytes
poly
Prior art date
Application number
DK98942616T
Other languages
English (en)
Inventor
Andreas Thuenemann
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of DK1003559T3 publication Critical patent/DK1003559T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
DK98942616T 1997-07-25 1998-07-24 Immobilisering af vitamin A-syre ved kationiske polyelektrolytter DK1003559T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19732139A DE19732139C2 (de) 1997-07-25 1997-07-25 Mesomorphe Komplexe aus Vitamin A-Säure und kationischen Polyelektrolyten, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
PCT/EP1998/004644 WO1999004821A2 (de) 1997-07-25 1998-07-24 Immobilisierung von vitamin-a-säure durch kationische polyelektrolyte

Publications (1)

Publication Number Publication Date
DK1003559T3 true DK1003559T3 (da) 2002-05-13

Family

ID=7836939

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98942616T DK1003559T3 (da) 1997-07-25 1998-07-24 Immobilisering af vitamin A-syre ved kationiske polyelektrolytter

Country Status (9)

Country Link
US (1) US6395284B1 (da)
EP (1) EP1003559B1 (da)
JP (1) JP2001510809A (da)
AT (1) ATE213649T1 (da)
CA (1) CA2298065A1 (da)
DE (2) DE19732139C2 (da)
DK (1) DK1003559T3 (da)
ES (1) ES2172192T3 (da)
WO (1) WO1999004821A2 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804321B1 (fr) * 2000-01-28 2003-08-15 Oreal Utilisation de derives de polyaminoacides pour traiter la seborrhee et les desordres cutanes associes
JP4870431B2 (ja) * 2003-08-20 2012-02-08 ワヒ、アショック、エル． 強化された静電気電荷型点鼻製品
WO2005063195A2 (en) * 2003-12-30 2005-07-14 Med Care S.R.L. Compositions comprising vitamins and/or derivatives thereof stabilised with olea europea extract and/or ionene polymers
EP1879552B1 (en) * 2005-03-14 2016-02-17 Biotegra, Inc. Drug delivery compositions comprising a polyelectrolyte complex within a polymeric matrix
JP5548362B2 (ja) * 2005-10-18 2014-07-16 株式会社アモーレパシフィック 油溶性活性成分を捕集した陽イオン性高分子ナノカプセル及びこれを含有する化粧料組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4371673A (en) * 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
US4999348A (en) * 1987-12-11 1991-03-12 Estee Lauder Inc. Liquid crystal containing cosmetic and pharmaceutical compositions and methods for utilizing such compositions
FR2719475B1 (fr) * 1994-05-05 1996-06-07 Oreal Composition cosmétique et/ou dermatologique à gélifiant polymérique cationique, ses utilisations notamment pour la dépigmentation de la peau.
DE4428641A1 (de) * 1994-08-12 1996-02-15 Basf Ag Mesomorphe Komplexe aus Polyelektrolyten und Tensiden, Verfahren zu ihrer Herstellung sowie Filme, Folien, Fasern, Formkörper und Beschichtungen hieraus
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun

Also Published As

Publication number Publication date
DE19732139C2 (de) 2002-10-10
DE19732139A1 (de) 1999-01-28
JP2001510809A (ja) 2001-08-07
ATE213649T1 (de) 2002-03-15
DE59803212D1 (de) 2002-04-04
EP1003559B1 (de) 2002-02-27
US6395284B1 (en) 2002-05-28
ES2172192T3 (es) 2002-09-16
WO1999004821A3 (de) 1999-04-15
EP1003559A2 (de) 2000-05-31
WO1999004821A2 (de) 1999-02-04
CA2298065A1 (en) 1999-02-04

Similar Documents

Publication Publication Date Title
AU3804500A (en) 2-amino-6-anilino-purines and their use as medicaments
NO20014662D0 (no) Fremgangsmåter og preparater for behandling av faste tumorer
TR200201442T2 (tr) Ağrı hafifletme, kemik kanseri terapisi ve kemik yüzeyinin sağlıklı tutulması için kireçlenmiş hedef dokulara yönelik radyum-223 hazırlanması ve kullanımı.
BR0107705A (pt) Uso de uma alìquota de sangue modificado em um paciente para tratamento de falência cardìaca congestiva
PT933995E (pt) Metodo para tratamento de lesao endotelial
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
MY164077A (en) Compositions and uses of et743 for treating cancer
BR0211978A (pt) Terapia de combinação para o tratamento de câncer
DE602004016376D1 (de) Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
AU2001287850A1 (en) Iron compositions
GEP20043202B (en) Resorcinol Derivatives
DK1003559T3 (da) Immobilisering af vitamin A-syre ved kationiske polyelektrolytter
IL138290A0 (en) Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
BR0115727A (pt) Formulações dermatológicas
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
GEP20043231B (en) Resorcinol Composition
DE69935037D1 (de) Chelatiertes 8-hydroxychinolin zur behandlung von epithelialen verletzungen
BR0111740A (pt) Terapia combinada contra tumores que compreende derivados de distamicina acriloila substituìda e agentes de alquilação
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
WO2000037065A3 (en) Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs
IS5231A (is) Vefjaþáttur sem hefur áhrif á blóðæðarmyndun
BR9007080A (pt) Aplicacao de derivados de 1,2-benzopirona para o tratamento de tumores malignos no homem
GEP20012408B (en) Means for Treatment of Psoriasis
EP1714661A3 (en) Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
Korovin Use of radiotherapy at treatment of skin melanoma metastases in lungs.; Primenenie luchevoj terapii pri lechenii metastazov melanomy kozhi v legkie.